Keyphrases
Adjuvant Immunotherapy
58%
Advanced Melanoma
29%
Anti-PD-1
29%
Arginase-1 (Arg-1)
29%
Arthritis
29%
Autoimmune Hepatitis
16%
Bcl-xL
29%
Checkpoint Inhibitor Colitis
38%
Checkpoint Inhibitors
50%
Colitis
15%
Common Terminology Criteria for Adverse Events (CTCAE)
19%
Confidence Interval
40%
Diarrhea
21%
Enteritis
19%
Fecal Microbiota Transplantation
29%
First-in-man Study
29%
Gastroenteritis
29%
Health-related Quality of Life
29%
Hepatitis
29%
Hepatotoxicity
29%
IL-6 Blockade
29%
Immune Checkpoint Inhibitors
73%
Immune Modulatory Vaccine
29%
Immune-related
29%
Immune-related Adverse Events
21%
Indoleamine 2,3-dioxygenase 1 (IDO1)
29%
Infliximab
15%
Ipilimumab
58%
Large B-cell Lymphoma
29%
Locally Advanced Prostate Cancer
29%
Medical Management
29%
Melanoma
61%
Mental Health
29%
Metastatic Melanoma
76%
Metastatic Tumor
29%
Monotherapy
27%
Nivolumab
58%
Peptide Vaccine
29%
Phase I Trial
29%
Programmed Death
29%
Quality of Life
29%
Real Patients
64%
Risk Factors
29%
Stage III-IV
35%
Targeting Peptide
29%
Tocilizumab
29%
Tofacitinib
29%
Tumor-infiltrating Lymphocyte Therapy
29%
Tumor-infiltrating Lymphocytes
29%
Vaccination
28%
Pharmacology, Toxicology and Pharmaceutical Science
Adjuvant
9%
Adverse Event
43%
Antibiotics
14%
Arginase 1
29%
Arthritis
29%
Aspartate Aminotransferase
7%
B Cell Lymphoma
29%
CD8 Antigen
24%
Clinical Study
32%
Colitis
43%
Combination Therapy
7%
Comorbidity
19%
Cross Sectional Study
9%
Cytokine
7%
Diarrhea
15%
Disease
9%
Elimination
8%
Enteritis
14%
Enterocolitis
29%
Feces microflora
29%
Glucocorticoid
32%
Hepatotoxicity
29%
Immune Checkpoint Inhibitor
100%
Immunogenicity
14%
Immunosuppressive Agent
28%
Immunotherapy
58%
Indoleamine 2,3 Dioxygenase
29%
Infection
14%
Infliximab
11%
Intraperitoneal Injection
9%
Ipilimumab
47%
Malignant Neoplasm
22%
Melanoma
87%
Metastatic Melanoma
79%
Monotherapy
24%
Neoplasm
53%
Nivolumab
64%
Overall Survival
8%
Peptide Vaccine
29%
Phase I Trials
29%
Preclinical Study
9%
Progression Free Survival
13%
Prostate Cancer
29%
Recurrent Disease
20%
Remission
8%
Solid Malignant Neoplasm
29%
Tocilizumab
29%
Tofacitinib
29%
Vaccination Policy
41%
Vedolizumab
7%
Medicine and Dentistry
Adverse Event
18%
Antibiotic Therapy
14%
Arginase 1
29%
Arthritis
29%
Aspartate Aminotransferase
7%
Clinical Study
32%
Colitis
43%
Combination Therapy
7%
Cytotoxic T-Cell
9%
Diarrhea
15%
Disease
9%
Enteritis
14%
Enterocolitis
29%
Fecal Microbiota Transplantation
29%
Glucocorticoid
32%
Immune Checkpoint Inhibitor
92%
Immune-Related Adverse Events
15%
Immunogenicity
9%
Immunosuppressant
14%
Immunosuppressive Drug
13%
Immunotherapy
29%
Indoleamine 2,3 Dioxygenase
29%
Infection
14%
Infliximab
11%
Interleukin-6
29%
Ipilimumab
33%
Liver Enzyme
7%
Liver Toxicity
29%
Malignant Neoplasm
12%
Mental Health
29%
Metastatic Melanoma
68%
Monotherapy
17%
Neoplasm
13%
Nivolumab
42%
Nodular Melanoma
58%
Overall Survival
8%
Peptide Vaccine
29%
Peripheral Blood Mononuclear Cell
7%
Phase I Trials
29%
Progression Free Survival
13%
Quality of Life
29%
Solid Malignant Neoplasm
29%
Steroid Treatment
7%
T Cell
32%
T-Helper Cell
9%
Tocilizumab
29%
Tofacitinib
29%
Tumor Infiltrating Lymphocyte
29%
Tumor Microenvironment
7%
Vedolizumab
7%